What You Should Know
- The Launch: Flatiron Health has expanded its Panoramic platform to include prostate cancer datasets from the UK and Germany, creating a unified, global standard for Real-World Evidence (RWE).
- The Scale: The dataset encompasses nearly 400,000 patients across the US and Europe. It leverages proprietary AI and Large Language Models (LLMs) to extract unstructured data from Electronic Health Records (EHRs).
- The Depth: Unlike standard claims data, this platform captures deep clinical details crucial for precision medicine, including PSMA PET scan results, PSA values, and 19 HRR genes.
Breaking the Silos with AI
Cancer biology is universal, but cancer data is fiercely local. A patient in Berlin and a patient in Boston might have the same tumor mutation, but their medical records live in completely different universes—separated by language, regulation, and software format.
The challenge with global research isn’t just access; it’s translation. Not linguistic translation, but clinical translation. A doctor’s note in a German hospital looks very different from one in a British NHS trust.
Flatiron is using AI and Large Language Models (LLMs) to solve this. The technology ingests unstructured notes and structured EHR data, normalizing it into a “common data model.”
- The result: A dataset of nearly 400,000 patients that researchers can query as if it were a single population.
- The depth: It includes granular details often lost in translation, such as PSMA PET scans (a cutting-edge imaging technique) and HRR gene mutations (critical for new targeted therapies).
The Roadmap: Breast and Lung Next
This launch focuses on Genitourinary cancers (prostate and bladder), but it is just the first step in a larger global strategy. Flatiron has confirmed plans to roll out similar global datasets for Breast Cancer and Non-Small Cell Lung Cancer (NSCLC) in 2027.
“Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence.” said Kate Estep, Chief Product Officer at Flatiron Health. “By unifying fragmented global records into a single evidence platform, we are fundamentally changing how our customers develop therapies and—most importantly—when patients can access them.”
